Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · Real-Time Price · USD
17.63
+2.55 (16.91%)
At close: Oct 28, 2025, 4:00 PM EDT
18.60
+0.97 (5.50%)
After-hours: Oct 28, 2025, 7:57 PM EDT
Nanobiotix Revenue
Nanobiotix had revenue of 26.64M EUR in the half year ending June 30, 2025, with 708.93% growth. This brings the company's revenue in the last twelve months to 10.16M, down -75.93% year-over-year. In the year 2024, Nanobiotix had annual revenue of -7.19M, down -119.86%.
Revenue (ttm)
10.16M EUR
Revenue Growth
-75.93%
P/S Ratio
72.95
Revenue / Employee
94,065 EUR
Employees
108
Market Cap
870.31M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | -7.19M | -43.40M | -119.86% |
| Dec 31, 2023 | 36.21M | 31.43M | 658.12% |
| Dec 31, 2022 | 4.78M | 2.13M | 80.43% |
| Dec 31, 2021 | 2.65M | 322.00K | 13.85% |
| Dec 31, 2020 | 2.33M | -216.00K | -8.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
NBTX News
- 27 days ago - NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer - GlobeNewsWire
- 4 weeks ago - NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC - GlobeNewsWire
- 5 weeks ago - Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday - Benzinga
- 5 weeks ago - Nanobiotix: Today's Data Readout For Radiation Therapy Enhances Bull Case - Seeking Alpha
- 5 weeks ago - Nanobiotix S.A. - Special Call - Seeking Alpha
- 5 weeks ago - NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1 - GlobeNewsWire
- 2 months ago - Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire